Prioritizing the worries of AML patients: Quantifying patient experience using best–worst scaling.

PATIENTS' attitudes; ACUTE myeloid leukemia; HEALTH services accessibility; CAREGIVERS; PATIENT-centered care; PATIENT experience

Context: Although patients with acute myeloid leukemia (AML) experience significant toxicities and poor outcomes, few studies have quantified patients' experience. Methods: A community‐centered approach was used to develop an AML‐specific best–worst scaling (BWS) instrument involving 13 items in four domains (psychological, physical, decision‐making, and treatment delivery) to quantify patient worry. A survey of patients and caregivers was conducted using the instrument. Data were analyzed using conditional logistic regression. Results: The survey was completed by 832 patients and 237 caregivers. Patients were predominantly white (88%), married/partnered (72%), and in remission (95%). The median age was 55 years (range: 19–87). Median time since diagnosis was 8 years (range: 1–40). Patients worried most about "the possibility of dying from AML" (BWS score = 15.5, confidence interval [CI] [14.2–16.7]) and "long‐term side effects of treatments" (14.0, CI [12.9–15.2]). Patients found these items more than twice as worrisome as all items within the domains of care delivery and decision‐making. Patients were least worried about "communicating openly with doctors" (2.50, CI [1.97–3.04]) and "having access to the best medical care" (3.90, CI [3.28–4.61]). Caregiver reports were highly correlated to patients' (Spearman's ρ = 0.89) though noted significantly more worry about the possibility of dying and spending time in the hospital. Conclusion: This large convenience sample demonstrates that AML patients have two principal worries: dying from their disease and suffering long‐term side effects from treatment. To better foster patient‐centered care, therapeutic decision‐making and drug development should reflect the importance of both potential outcomes. Further work should explore interventions to address these worries. [ABSTRACT FROM AUTHOR]

Copyright of Psycho-Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)